SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.43-0.7%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg2/12/2007 2:09:17 AM
   of 2240
 
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.

Blood. 2007 Feb 8

Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen L.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Although self-reactive T cell precursors can be eliminated upon recognition of self-antigen presented in thymus, this central tolerance process is often incomplete and additional mechanisms are required to prevent autoimmunity. Recent studies implicate that the interaction between B7-H1 and its receptor PD-1 on activated T cells plays an important role in the inhibition of T cell responses in peripheral organs. Here we show that, before their exit to the periphery, T cells in lymphoid organs rapidly up-regulate PD-1 upon tolerogen recognition. Ablation of the B7-H1 and PD-1 interaction when T cells are still in lymphoid organs prevents anergy. Furthermore, blockade of B7-H1 and PD-1 interaction could render anergic T cells responsive to antigen. Our results thus reveal previously unappreciated roles of B7-H1 and PD-1 Interaction in the control of initiation and reversion of T cell anergy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext